AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Tuberculosis: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan AfricaNCT04618198 · results posted 2026-09-09 · University of Virginia · 437 people · tests Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisNCT02563327 · results posted 2026-08-27 · Centers for Disease Control and Prevention · 2516 people · tests Rifapentine, Moxifloxacin, Rifampin, Isoniazid Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803 · results posted 2026-06-10 · AN2 Therapeutics, Inc · 177 people · tests Epetraborole, Placebo

Want these every week? Follow tuberculosis and get a note on your phone with the new trials and papers.

🔔 Follow tuberculosis
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy